ETR:SBSStratec Stock Price, Forecast & News

€82.00

-0.10 (-0.12 %)

(As of 06/3/2020 12:49 PM ET)

Add

Compare

Today's Range

€81.30

Now: €82.00▼

€83.50

50-Day Range

€78.90

MA: €85.65▼

€91.70

52-Week Range

€46.40

Now: €82.00▼

€93.00

Volume10,965 shs

Average Volume6,253 shs

Market Capitalization$986.07 million

P/E Ratio58.33

Dividend Yield1.02%

BetaN/A

Stratec SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. The company operates through three segments: Instrumentation, Diatron, and Consumables. The Instrumentation segment designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Consumables segment develops and sells scientific materials, such as nucleic acid purification; and designs and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technology. Stratec SE also develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.

Beat the Market (BTM) Rank^™

1.4 Analyst's Opinion

Consensus Rating
Stratec has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of €85.25, Stratec has a potential upside of 4.0% from its current price of €82.00.
Amount of Analyst Coverage
Stratec has only been the subject of 4 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Stratec has received 140 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Stratec has received 109 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Stratec has received 56.22% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Stratec and other stocks. Vote “Outperform” if you believe SBS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SBS will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Leadership
Stratec is a leading dividend payer. It pays a dividend yield of 1.02%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Stratec does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Stratec is 59.53 %. This payout ratio is at a healthy, sustainable level, below 75%.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Stratec insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Stratec is 58.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.05.
Price to Earnings Ratio vs. Sector
The P/E ratio of Stratec is 58.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.45.
Price to Book Value per Share Ratio
Stratec has a P/B Ratio of 6.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.34 out of 5 stars

Industry, Sector and Symbol

Stock Exchange ETR

Industry Medical Devices

Sub-IndustryN/A

SectorMedical

Current SymbolETR:SBS

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.stratec.com

Phone+49-7082-79160

Debt

Debt-to-Equity Ratio66.24

Current Ratio3.67

Quick Ratio2.25

Price-To-Earnings

Trailing P/E Ratio58.33

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$231.58 million

Price / Sales4.26

Cash Flow€2.83 per share

Price / Cash Flow28.94

Book Value€13.11 per share

Price / Book6.26

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees1,158

Outstanding Shares12,025,300

Market Cap$986.07 million

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive SBS News and Ratings via Email

Sign-up to receive the latest news and ratings for SBS and its competitors with MarketBeat's FREE daily newsletter.

Stratec (ETR:SBS) Frequently Asked Questions

How has Stratec's stock been impacted by COVID-19 (Coronavirus)?

Stratec's stock was trading at €64.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SBS shares have increased by 28.1% and is now trading at €82.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Stratec?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stratec in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Stratec.

When is Stratec's next earnings date?

Stratec is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Stratec.

What price target have analysts set for SBS?

4 Wall Street analysts have issued twelve-month target prices for Stratec's shares. Their forecasts range from €69.00 to €97.00. On average, they expect Stratec's share price to reach €85.25 in the next year. This suggests a possible upside of 4.0% from the stock's current price. View analysts' price targets for Stratec.

Has Stratec been receiving favorable news coverage?

News headlines about SBS stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Stratec earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future. View the latest news aboutStratec.

Who are some of Stratec's key competitors?

Some companies that are related to Stratec include ConvaTec Group (CTEC), Avita Medical (AVH), Zynex (ZYXI), Draegerwerk AG & Co KGaA (DRW3), Avacta Group (AVCT), Creo Medical Group (CREO), Hamilton Thorne (HTL), Imricor Med SYS Cdi 1:1 US Person Prohibited Excluding QIB (IMR), Medica Group (MGP), Electromed (ELMD), Electromed (ELMD), Cyclopharm (CYC), Patient Home Monitoring (PTQ), Advanced Oncotherapy (AVO) and Somnomed (SOM). View all competitors.

What other stocks do shareholders of Stratec own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stratec investors own include Great Portland Estates (GPOR), Gogo (GOGO), Depomed (DEPO), Cenovus Energy (CVE), China Hydroelectric Co. (USD) (CHC), Bio-Rad Laboratories (BIO), Berkshire Hills Bancorp (BHLB), ASGN (ASGN), Apptio (APTI) and Anadarko Petroleum (APC).

Who are Stratec's key executives?

Stratec's management team includes the following people:

Mr. Marcus Wolfinger, Chairman of Board of Management & CEO (Age 52)
Dr. Robert Siegle, Director of Fin. & HR and Member of Board of Management (Age 52)
Dr. Claus Vielsack, Director of Product Devel. & Member of Board of Management (Age 52)
Mr. Hermann Leistner, Founder & Advisor (Age 73)
Sandra Eberle, Head of Investor Relations

What is Stratec's stock symbol?

Stratec trades on the ETR under the ticker symbol "SBS."

What is Stratec's stock price today?

One share of SBS stock can currently be purchased for approximately €82.00.

How big of a company is Stratec?

Stratec has a market capitalization of $986.07 million and generates $231.58 million in revenue each year. Stratec employs 1,158 workers across the globe.

What is Stratec's official website?

The official website for Stratec is www.stratec.com.

How can I contact Stratec?

Stratec's mailing address is Gewerbestr. 37, BIRKENFELD, 75217, Germany. The company can be reached via phone at +49-7082-79160.

This page was last updated on 6/3/2020 by MarketBeat.com Staff